The Agentic Era: Why Biopharma Must Embrace Artificial Intelligence That Acts, Not Just Informs

Agentic artificial intelligence (AI), characterized by its capacity for autonomous task execution rather than mere assistance, heralds a fundamental paradigm shift in biopharmaceutical operations. From accelerating discovery and streamlining development to revolutionizing commercialization and governance, agentic AI systems are poised to redefine the industry's core processes. This editorial explores the burgeoning role of agentic AI as a novel operating model for biopharma, highlighting its increasing relevance across critical functions, including drug development, clinical trials, regulatory affairs, and strategic decision-making. As regulatory frameworks adapt to accommodate AI-driven methodologies, agentic systems are positioned to supersede legacy infrastructures with self-directed, adaptive engines of innovation. The future of biopharma will be defined not only by groundbreaking molecular discoveries but also by the intelligent orchestration of these advancements through autonomous machines.